Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia

Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00429975

Enrollment

Registered

2007-02-01

Start date

2004-08-31

Completion date

2005-09-30

Last updated

2007-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia, Pneumococcal

Keywords

fluorquinolones,, b-lactams,, immunomodulation.

Brief summary

The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine production in patients with pneumococcal pneumonia.

Detailed description

Bacterial alveolar invasion is followed by a compartmentalized inflammatory response. Data suggest that some antimicrobials may induce a differential release of cytokines, with the potential of either accelerating or down regulating cytokine production. The aim of our study was to compare the effects of ceftriaxone compared with levofloxacin on cytokine systemic concentrations in patients with pneumococcal pneumonia.

Interventions

DRUGlevofloxacin

DRUGceftriaxone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with an acute febrile respiratory illness accompanied by a new radiographic infiltrate consistent with this diagnosis. * and with a confirmed pneumococcal aetiology

Exclusion criteria

* age \< 18 years, * pneumonia distal to endobronchial obstruction, * pulmonary tuberculosis, * bronchiectasis, * known allergy to B-lactams or fluoroquinolones, * underlying systemic autoimmune disease * immunocompromised states including patients on maintenance oral corticosteroids, HIV infection, * pregnancy, * patients that received antimicrobial therapy in the 15 days preceding the current episode and those who had received fluoroquinolones in the last month, or non steroidal anti-inflammatory therapy in the last two weeks. * Patients with renal failure (serum creatinine \> 2 mg / dL), * and patients with a documented pneumococcal pneumonia in the previous 4 weeks

Design outcomes

Primary

Measure	Time frame
Circulating levels of pro and anti-inflammatory cytokines at 0h, 24, 72 h and 120 h from inclusion	—

Secondary

Measure	Time frame
the relationship between cytokine expression, clinical variables and severity of disease.	—

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026